Literature DB >> 26648070

Adoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells.

Conrad R Y Cruz, Catherine M Bollard1.   

Abstract

The development of novel T cell therapies to target leukemia has facilitated the translation of this approach for hematologic malignancies. Different methods of manufacturing leukemia-specific T cells have evolved, along with additional measures to increase the safety of this therapy. This is an overview of expanded T cell therapeutics with a focus on how the manufacturing strategies have been refined, and where the research is heading. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Cell therapy; ex vivo expanded T cells.; leukemia antigens

Mesh：

Year:  2017        PMID： 26648070      PMCID： PMC5016253          DOI： 10.2174/1389450117666160209143529

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN： 1389-4501            Impact factor:   3.465


  95 in total

1.  Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy.

Authors:  Juhua Zhou; Xinglei Shen; Jianping Huang; Richard J Hodes; Steven A Rosenberg; Paul F Robbins
Journal:  J Immunol       Date:  2005-11-15       Impact factor: 5.422

2.  CD134-allodepletion allows selective elimination of alloreactive human T cells without loss of virus-specific and leukemia-specific effectors.

Authors:  Xupeng Ge; Julia Brown; Megan Sykes; Vassiliki A Boussiotis
Journal:  Biol Blood Marrow Transplant       Date:  2008-05       Impact factor: 5.742

3.  Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4.

Authors:  Conrad R Cruz; Ulrike Gerdemann; Ann M Leen; Jessica A Shafer; Stephanie Ku; Benjamin Tzou; Terzah M Horton; Andrea Sheehan; Amanda Copeland; Anas Younes; Cliona M Rooney; Helen E Heslop; Catherine M Bollard
Journal:  Clin Cancer Res       Date:  2011-09-09       Impact factor: 12.531

4.  Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation.

Authors:  Fabio Ciceri; Chiara Bonini; Sarah Marktel; Elisabetta Zappone; Paolo Servida; Massimo Bernardi; Alessandra Pescarollo; Attilio Bondanza; Jacopo Peccatori; Silvano Rossini; Zulma Magnani; Monica Salomoni; Claudia Benati; Maurilio Ponzoni; Luciano Callegaro; Paolo Corradini; Marco Bregni; Catia Traversari; Claudio Bordignon
Journal:  Blood       Date:  2007-02-27       Impact factor: 22.113

Review 5.  Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia.

Authors:  Marie Bleakley; Stanley R Riddell
Journal:  Immunol Cell Biol       Date:  2011-02-08       Impact factor: 5.126

Review 6.  T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing.

Authors:  Coen Govers; Zsolt Sebestyén; Miriam Coccoris; Ralph A Willemsen; Reno Debets
Journal:  Trends Mol Med       Date:  2010-02-01       Impact factor: 11.951

7.  Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes.

Authors:  Patrick J Hanley; Conrad Russell Young Cruz; Barbara Savoldo; Ann M Leen; Maja Stanojevic; Mariam Khalil; William Decker; Jeffrey J Molldrem; Hao Liu; Adrian P Gee; Cliona M Rooney; Helen E Heslop; Gianpietro Dotti; Malcolm K Brenner; Elizabeth J Shpall; Catherine M Bollard
Journal:  Blood       Date:  2009-05-14       Impact factor: 22.113

8.  WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation.

Authors:  G Weber; J Karbach; S Kuçi; H Kreyenberg; A Willasch; E Koscielniak; T Tonn; T Klingebiel; W S Wels; E Jäger; P Bader
Journal:  Leukemia       Date:  2009-04-09       Impact factor: 11.528

Review 9.  Adoptive immunotherapy for posttransplantation viral infections.

Authors:  Catherine M Bollard; Ingrid Kuehnle; Ann Leen; Cliona M Rooney; Helen E Heslop
Journal:  Biol Blood Marrow Transplant       Date:  2004-03       Impact factor: 5.742

10.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.

Authors:  H J Kolb; A Schattenberg; J M Goldman; B Hertenstein; N Jacobsen; W Arcese; P Ljungman; A Ferrant; L Verdonck; D Niederwieser; F van Rhee; J Mittermueller; T de Witte; E Holler; H Ansari
Journal:  Blood       Date:  1995-09-01       Impact factor: 22.113
View more
  2 in total

1.  T cells targeting multiple tumor-associated antigens as a postremission treatment to prevent or delay relapse in acute myeloid leukemia.

Authors:  Lei Xue; Yan Hu; Jian Wang; Xin Liu; Xingbing Wang
Journal:  Cancer Manag Res       Date:  2019-07-16       Impact factor: 3.989

Review 2.  Neoantigen: A New Breakthrough in Tumor Immunotherapy.

Authors:  Zheying Zhang; Manman Lu; Yu Qin; Wuji Gao; Li Tao; Wei Su; Jiateng Zhong
Journal:  Front Immunol       Date:  2021-04-16       Impact factor: 7.561
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.